Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: the UCON randomised controlled trial and mechanism of action study›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: the UCON randomised controlled trial and mechanism of action study · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 17 min read

  1. Shapley M, Jordan K, Croft PR. An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract 2004;54(502):359–63.15113519
  2. Kaloo P, Davies, Sally. Case discussion: heavy menstrual bleeding in primary care and beyond. Br J Fam Med 2014;2(4):14–7.
  3. Schoep ME, Nieboer TE, van der Zanden M, Braat DDM, Nap AW. The impact of menstrual symptoms on everyday life: a survey among 42,879 women. Am J Obstet Gynecol 2019;220(6):569.e1–e7. 10.1016/j.ajog.2019.02.048
  4. National Institute for Health and Care Excellence (NICE). Heavy Menstrual Bleeding: Assessment and management. NICE Clinical Guidelines [ CG 44 ]. London: NICE; 2016.
  5. Wear White Again. A Guide to Heavy Menstrual Bleeding. URL: https://www.wearwhiteagain.co.uk/wp-content/uploads/2018/09/Heavy-Period-Guide-compressed.pdf (accessed 21 January 2023).
  6. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007;10(3):183–94. 10.1111/j.1524-4733.2007.00168.x17532811
  7. Munro MG, Critchley HOD, Fraser IS, Committee FMD. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet 2018;143(3):393–408. 10.1002/ijgo.12666
  8. Kai J DB, Vinogradova Y, Hiken N, Gupta J, Daniels J. Medical treatment for heavy menstrual bleeding in primary care: 10-year data from the ECLIPSE trial. Br J Gen Pract 2022;72(725):e857–64.36376071
  9. National Institute for Health and Care Excellence (NICE). Heavy Menstrual Bleeding: Assessment and management. NICE Guideline [ NG88 ]. London: NICE; 2021.
  10. Gupta JK, Daniels JP, Middleton LJ, Pattison HM, Prileszky G, Roberts TE, et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. Health Technol Assess 2015;19(88):i–xxv, 1–118. 10.3310/hta19880
  11. Bofill Rodriguez M, Lethaby A, Jordan V. Progestogen‐releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2020;6:CD002126. 10.1002/14651858.CD002126.pub432529637
  12. Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev 2013;2:CD008994. 10.1002/14651858.CD008994.pub2
  13. Abdel-Aleem H, d’Arcangues C, Vogelsong KM, Gulmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007;4:CD003449. 10.1002/14651858.CD003449.pub3
  14. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368(2):128–37. 10.1056/NEJMoa120472423301731
  15. Whitaker L, Critchley HO. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol 2016;34:54–65. 10.1016/j.bpobgyn.2015.11.01226803558
  16. Kai J, Middleton L, Daniels J, Pattison HM, Tryposkiadis K, Gupta J. Usual medical treatments or levonorgestrel-IUS for women with heavy menstrual bleeding: long-term randomised pragmatic trial in primary care. Br J Gen Pract 2016;6(653):e861–70. 10.3399/bjgp16X687577
  17. Cooper K, Breeman S, Scott NW, Scotland G, Clark J, Hawe H, et al. Laparoscopic supracervical hysterectomy versus endometrial ablation for women with heavy menstrual bleeding (HEALTH): a parallel-group, open-label, randomised controlled trial. Lancet 2019;394(10207):1425–36. 10.1016/S0140-6736(19)31790-831522846
  18. Wagenfeld A, Saunders PTK, Whitaker L, Critchley HOD. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets 2016;20(9):1045–54. 10.1080/14728222.2016.118036827138351
  19. Baird DT, Thong KJ, Hall C, Cameron ST. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days. Hum Reprod 1995;10(9):2270–6. 10.1093/oxfordjournals.humrep.a1362838530650
  20. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92(9):3582–9. 10.1210/jc.2006-281617579200
  21. Critchley HOD, Chodankar RR. 90 years pf progesterone: selective progesterone receptor modulators in gynaecological therapies. J Mol Endocrinol 2020;65(1):T15–33. 10.1530/JME-19-023832599565
  22. Murji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017;4:CD010770. 10.1002/14651858.CD010770.pub228444736
  23. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366(5):409–20. 10.1056/NEJMoa110318222296075
  24. Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366(5):421–32. 10.1056/NEJMoa110318022296076
  25. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012;31(6):556–69. 10.1097/PGP.0b013e318251035b23018219
  26. De Milliano I, Van Hattum D, Ket JCF, Huirne JAF, Hehenkamp WJK. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol 2017;214:56–64. 10.1016/j.ejogrb.2017.04.04228482329
  27. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merinio M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21(5):591–8. 10.1038/modpathol.2008.1918246050
  28. Whitaker LH, Murray AA, Matthews R, Shaw G, Williams AR, Saunders PT, Critchley HO. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod 2017;32(3):531–43. 10.1093/humrep/dew35928130434
  29. Fauser BC, Donnez J, Bouchard P, Barlow DH, Vázquez F, Arriagada P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLOS ONE 2017;12(3):e0173523. 10.1371/journal.pone.017352328267814
  30. European Medicines Agency (EMA). Esmya: New Measures to Minimise Risk of Rare but Serious Liver Injury. 2018. [Press release EMA/482522/2018.] URL: https://www.ema.europa.eu/en/documents/press-release/esmya-new-measures-minimise-risk-rare-serious-liver-injury_en.pdf (accessed 21 January 2023).
  31. European Medicines Agency (EMA). PRAC Recommends Revoking Marketing Authorisation of Ulipristal Acetate for Uterine Fibroids 2020 2020. URL: https://www.ema.europa.eu/en/news/prac-recommends-revoking-marketing-authorisation-ulipristal-acetate-uterine-fibroids (accessed 21 January 2023).
  32. Middelkoop MA, Bet PM, Drenth JPH, Huirne JAF, Hehenkamp WJK. Risk-efficacy balance of ulipristal acetate compared to surgical alternatives. Br J Clin Pharmacol 2021;87(7):2685–97. 10.1111/bcp.1470833341097
  33. Whitaker LHR, Middleton LJ, Daniels JP, Williams ARW, Priest L, Odedra S, et al. Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): A randomised controlled phase III trial. EClinicalMedicine 2023;60:101995. 10.1016/j.eclinm.2023.10199537251622
  34. DAMOCLES Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005;365(9460):711–22. 10.1016/S0140-6736(05)17965-315721478
  35. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15(5):443–53. 10.1002/cpt19741554434597226
  36. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18(1):61–8. 10.1093/humrep/deg02212525442
  37. Croxatto HB, Kovács L, Massai R, Resch BA, Fuentealba B, Salvatierra AM, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998;13(4):793–8. 10.1093/humrep/13.4.7939619526
  38. Stewart EA, Diamond MP, Williams ARW, Carr BR, Myers ER, Feldman RA, et al. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Hum Reprod 2019;34(4):623–34. 10.1093/humrep/dez00730865281
  39. Medicines and Healthcare products Regulatory Agency (MHRA). Esmya (Ulipristal Acetate) and Risk of Serious Liver Injury: New Restrictions to Use and Requirements for Liver Function Monitoring before, during, and after Treatment. 2018. URL: https://www.gov.uk/drug-safety-update/esmya-ulipristal-acetate-and-risk-of-serious-liver-injury-new-restrictions-to-use-and-requirements-for-liver-function-monitoring-before-during-and-after-treatment (accessed 21 January 2023).
  40. Goldstuck ND. Clarification of the role of the Jaydess(Skyla) LNG-IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems. Expert Rev Med Devices 2017;14(8):593–9. 10.1080/17434440.2017.135016928675069
  41. Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of women on the impact of menorrhagia on their health using multi‐attribute utility assessment. Br J Obstet Gynaecol 1998;105(11):1155–9. 10.1111/j.1471-0528.1998.tb09968.x9853763
  42. Higham JM, O’Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97(8):734–9. 10.1111/j.1471-0528.1990.tb16249.x2400752
  43. Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 2002;99(2):290–300. 10.1016/s0029-7844(01)01702-111814511
  44. Thirlaway K, Fallowfield L, Cuzick J. The sexual activity questionnaire: a measure of women’s sexual functioning. Qual Life Res 1996;5(1):81–90. 10.1007/BF004359728901370
  45. Herdman M, Gudex C, Lloyd A, Janssen Mf, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20(10):1727–36. 10.1007/s11136-011-9903-x21479777
  46. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41(5):582–92. 10.1097/00005650-200305000-0000412719681
  47. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73(1):13–22. 10.1093/biomet/73.1.13
  48. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34(6):585–612. 10.1038/bjc.1976.220795448
  49. Chodankar RR, Murray A, Nicol M, Whitaker LHR, Williams ARW, Critchley HOD. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible. Fertil Steril 2021;116(3):882–95. 10.1016/j.fertnstert.2021.02.00833865567
  50. Yin K, Whitaker L, Hojo E, McLenachan S, Walker J, McKillop G, et al. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB). Human Reproduction Open 2023;3:hoad021. 10.1093/hropen/hoad021
  51. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18(4):502–19. 10.1210/edrv.18.4.03089267762
  52. Critchley HOD, Maybin JA, Armstrong GM, Williams ARW. Physiology of the endometrium and regulation of menstruation. Physiol Rev 2020;100(3):1149–79. 10.1152/physrev.00031.201932031903
  53. Lusher SJ, Raaijmakers HC, Vu-Pham D, Dechering K, Lam TW, Brown AR, et al. Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators. J Biol Chem 2011;286(40):35079–86. 10.1074/jbc.M111.27302921849509
  54. Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BCJM, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014;101(6):1565-73.e1-18. 10.1016/j.fertnstert.2014.02.00824630081
  55. Noyes RW HA, Rock J. Dating the endometrial biopsy. Fertil Steril 1950;1:3–25.
  56. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011;113(1):3–13. 10.1016/j.ijgo.2010.11.01121345435
  57. Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, et al. Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochem J 1996;313(Pt 3):1007–17. 10.1042/bj31310078611140
  58. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep 2017;7(1):16878. 10.1038/s41598-017-17204-529203879
  59. Schultze-Mosgau M-H, Ploeger BA, Frei M, Höchel J, Rottmann A. Clinical pharmacokinetics and pharmacodynamics of the selective progesterone receptor modulator vilaprisan: a comprehensive overview. Clin Pharmacokinet 2021;61(1):1–16. 10.1007/s40262-021-01073-334569009
  60. Sutter G, Frei M, Schultze-Mosgau MH, Petersdorf K, Seitz C, Ploeger BA. Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. Br J Clin Pharmacol 2022;88(2):734–41. 10.1111/bcp.1501434327754
  61. Möller C, Bone W, Cleve A, et al. Discovery of vilaprisan (BAY 1002670): a highly potent and selective progesterone receptor modulator optimized for gynecologic therapies. ChemMedChem 2018;13(21):2271–80. 10.1002/cmdc.20180048730407750
  62. Lee MJ, Yun BS, Seong SJ, Kim ML, Jung YW, Kim MK, et al. Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Obstet Gynecol Sci 2017;60(1):69–73. 10.5468/ogs.2017.60.1.6928217674
  63. Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015;103(2):519–27.e3. 10.1016/j.fertnstert.2014.10.03825542821
  64. Donnez J, Courtoy GE, Donnez O, Dolmans M-M. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod Biomed Online 2018;37(2):216–23. 10.1016/j.rbmo.2018.04.04029706284
  65. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111(5):1129–36. 10.1097/AOG.0b013e3181705d0e18448745
  66. Ferrero S, Alessandri F, Vellone VG, Venturini PL, Leone Roberti Maggiore U. Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. Eur J Obstet Gynecol Reprod Biol 2016;205:43–7. 10.1016/j.ejogrb.2016.08.02127566221
  67. Nieman LKMD, Blocker WRN, Nansel TPD, Mahoney S, Reynolds J, Blithe D, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011;95(2):767–72.e2. 10.1016/j.fertnstert.2010.09.05921055739
  68. Woodhead N, Pounds R, Irani S, Pradhan P. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital. J Obstet Gynaecol 2018;38(6):813–7. 10.1080/01443615.2017.140592629526144
  69. Yun BS, Seong SJ, Jung YW, Kim ML, Bae HS, Kim MK, Shim SS. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate. Eur J Obstet Gynecol Reprod Biol 2018;224:133–6. 10.1016/j.ejogrb.2018.03.02629602142
  70. Netter A, Pauly V, Siles P, Pivano A, Vidal V, Agostini A. Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study. Reprod Biomed Online 2019;39(5):795–801. 10.1016/j.rbmo.2019.07.02831594689
  71. Thrippleton MJ, Munro KI, McKillop G, Newby DE, Marshall I, Roberts N, Critchley HOD. Unbiased and efficient estimation of the volume of the fibroid uterus using the Cavalieri method and magnetic resonance imaging. Reprod Sci 2015;22(1):15–22. 10.1177/193371911455345125332217
  72. Puddephat MJ. Computer Interface for Convenient Application of Stereological Methods for Unbiased Estimation of Volume and Surface Area: Studies Using MRI With Particular Reference to the Human Brain. PhD thesis. Liverpool: University of Liverpool; 1998.
  73. Gundersen HJ, Jensen EB, Kieu K, Nielsen J. The efficiency of systematic sampling in stereology – reconsidered. J Microsc 1999;193(Pt 3):199–211. 10.1046/j.1365-2818.1999.00457.x10348656
  74. Kieu K. Three Lectures on Systematic Geometric Sampling. Aarhus: Department of Theoretical Statistics, University of Aarhus; 1997.
  75. Kieu K, Souchet S, Istas J. Precision of systematic sampling and transitive methods. J Stat Plan Infer 1999;77:263–79.
  76. Matheron G. The Theory of Regionalized Variables and Its Application. Vol 5 of Les Cahiers du Centre de Morpholigie Mathematique de Fountainebleau ed. Paris: École National Supérieure des Mines de Paris; 1971.
  77. Gerke O. Reporting standards for a Bland-Altman agreement analysis: a review of methodological reviews. Diagnostics (Basel) 2020;10(5):334. 10.3390/diagnostics1005033432456091
  78. Kerns GJ. Power and Sample Size for Repeated Measures ANOVA with R. R bloggers blog. 20 October 2012. URL: https://www.r-bloggers.com/2012/01/power-and-sample-size-for-repeated-measures-anova-with-r/ (accessed 21 January 2023).
  79. Kelsey TW, Ginbey E, Chowdhury MM, Bath LE, Anderson RA, Wallace WH. A validated normative model for human uterine volume from birth to age 40 years. PLOS ONE 2016;11(6):e0157375. 10.1371/journal.pone.015737527295032
  80. Wu WC, Jain V, Li C, Giannetta M, Hurt H, Wehrli FW, Wang DJJ. In vivo venous blood T1 measurement using inversion recovery true-FISP in children and adults. Magn Reson Med 2010;64(4):1140–7. 10.1002/mrm.2248420564586
  81. Baggio S, Pomini P, Galeone F, Presti F, Santi L, Raffealli R, Franchi M. Influence of ulipristal acetate therapy on uterine fibroid-related symptoms and on uterine and fibroid volumes and vascularity indices assessed by ultrasound. J Ultrasound Med 2018;37(9):2215–23. 10.1002/jum.1457329498074
  82. Trefoux Bourdet A, Luton D, Koskas M. Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence. Int J Womens Health 2015;7:321–30. 10.2147/IJWH.S5001625848323
  83. Leyland NA. The selective progesterone receptor modulator, ulipristal acetate, in the management of symptomatic uterine fibroids. J Minim Invasive Gynecol 2015;22(6S):S73–4. 10.1016/j.jmig.2015.08.196
  84. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986;293(6543):359–62. 10.1136/bmj.293.6543.359
  85. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94(4):435–8. 10.1093/ajcp/94.4.4352220671
  86. DeWaay DJ, Syrop CH, Nygaard IE, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002;100(1):3–7. 10.1016/s0029-7844(02)02007-012100797
  87. Tsuda H, Kawabata M, Nakamoto O, Yamamoto K. Clinical predictors in the natural history of uterine leiomyoma: preliminary study. J Ultrasound Med 1998;17(1):17–20. 10.7863/jum.1998.17.1.179440103
  88. Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci 2008;105(50):19887–92. 10.1073/pnas.080818810519047643
  89. Baird DD, Patchel SA, Saldana TM, Umbach DM, Cooper T, Weiena G, Harmon QE. Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans. Am J Obstet Gynecol 2020;223(3):402.e1–18. 10.1016/j.ajog.2020.02.016
  90. Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med 2020;382(4):328–40. 10.1056/NEJMoa190435131971678
  91. O’Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96(2):189–95. 10.1038/sj.bjc.660351517211479
  92. O’Connor JP, Tofts PS, Miles KA, Parkes LM, Thompson G, Jackson A. Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol 2011;84(Spec Iss 2):S112–20. 10.1259/bjr/5516668822433822
  93. Thomassin-Naggara I, Balvay D, Cuenod CA, Darai E, Marsault C, Bazot M. Dynamic contrast-enhanced MR imaging to assess physiologic variations of myometrial perfusion. Eur Radiol 2010;20(4):984–94. 10.1007/s00330-009-1621-119820949
  94. Brookes JA, Redpath TW, Gilbert FJ, Murray AD, Staff RT. Accuracy of T1 measurement in dynamic contrast-enhanced breast MRI using two- and three-dimensional variable flip angle fast low-angle shot. J Magn Reson Imaging 1999;9(2):163–71. 10.1002/(sici)1522-2586(199902)9:2<163::aid-jmri3>3.0.co;2-l10077009
  95. Chen Y, Almarzouqi SJ, Morgan ML, Lee AG. T1-weighted image. In Schmidt-Erfurth U, Kohnen T, editors. Encyclopedia of Ophthalmology. Berlin: Springer; 2018. pp. 1747–50.
  96. Schmitt P, Griswold MA, Jakob PM, Kotas M, Gulani V, Flentje M, Haase A. Inversion recovery TrueFISP: quantification of T(1), T(2), and spin density. Magn Reson Med 2004;51(4):661–7. 10.1002/mrm.2005815065237
  97. Sourbron S, Sommer WH, Reiser MF, Zech CJ. Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Radiology 2012;263(3):874–83. 10.1148/radiol.1211033722623698
  98. Khalifa F, Soliman A, El-Baz A, Abou El-Ghar M, El-Diasty T, Gimel’farb G, et al. Models and methods for analyzing DCE-MRI: a review. Med Phys 2014;41(12):124301. 10.1118/1.489820225471985
  99. Sourbron SP, Buckley DL. Classic models for dynamic contrast-enhanced MRI. NMR Biomed 2013;26(8):1004–27. 10.1002/nbm.294023674304
  100. Leach MO, Brindle KM, Evelhoch JL, Griffieths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92(9):1599–610. 10.1038/sj.bjc.660255015870830
  101. Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006;21(9):2408–16. 10.1093/humrep/del15916720624
  102. Courtoy GE, Donnez J, Marbaix E, Dolmans MM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril 2015;104(2):426–34 e1. 10.1016/j.fertnstert.2015.04.02526003270
  103. Courtoy GE, Henriet P, Marbaix E, de Codt M, Luyckx M, Donnez J, Dolmans MM. Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. J Clin Endocrinol Metab 2018;103(4):1566–73. 10.1210/jc.2017-0229529408988
  104. Donnez J, Courtoy GE, Dolmans MM. Fibroid management in premenopausal women. journal article. Climacteric 2019;22(1):27–33. 10.1080/13697137.2018.154921630601065
  105. Shaked S, Jaffa AJ, Grisaru D, Elad D. Uterine peristalsis-induced stresses within the uterine wall may sprout adenomyosis. Biomech Model Mechanobiol 2015;14(3):437–44. 10.1007/s10237-014-0614-425217062
  106. Qu M, Lu P, Bellve K, Lifshitz LM, ZhuGe R. Mode switch of Ca(2 +) oscillation-mediated uterine peristalsis and associated embryo implantation impairments in mouse adenomyosis. Front Physiol 2021;12:744745. 10.3389/fphys.2021.74474534803733
  107. Essig M, Shiroishi MS, Nguyen TB, Saake M, Provenzale JM, Enterline D, et al. Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol 2013;200(1):24–34. 10.2214/ajr.12.954323255738
  108. Davenport MS, Heye T, Dale BM, Horvath JJ, Breault SR, Feuerlein S, et al. Inter- and intra-rater reproducibility of quantitative dynamic contrast enhanced MRI using TWIST perfusion data in a uterine fibroid model. J Magn Reson Imaging 2013;38(2):329–35. 10.1002/jmri.2397423239041
  109. Lewis JH, Cottu PH, Lehr M, Dick E, Shearer T, Rencher W, et al. Onapristone extended release: safety evaluation from phase I-II studies with an emphasis on hepatotoxicity. Drug Saf 2020;43(10):1045–55. 10.1007/s40264-020-00964-x32594454
  110. Bourdon M, Santulli P, Marcellin L, Maignien C, Maitrot-Mantelet L, Bordonne C, et al. Adenomyosis: an update regarding its diagnosis and clinical features. J Gynecol Obstet Hum Reprod 2021;50(10):102228. 10.1016/j.jogoh.2021.10222834520877
  111. Pinzauti S, Lazzeri L, Tosti C, Centini G, Orlandini C, Luisi S, et al. Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms. Ultrasound Obstet Gynecol 2015;46(6):730–6. 10.1002/uog.1483425728241
  112. Chapron C, Vannuccini S, Santulli P, Abrão MS, Carmona F, Fraser IS, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum Reprod Update 2020;26(3):392–411. 10.1093/humupd/dmz04932097456
  113. Office for National Statistics. Birth Characteristics in England and Wales: 2019. Annual Live Births in England and Wales by Sex, Birthweight, Gestational Age, Ethnicity and Month, Maternities by Place of Birth and with Multiple Births, and Stillbirths by Age of Parents and Calendar Quarter. URL: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthcharacteristicsinenglandandwales/2019#age-of-parents (accessed 23 January 2023).
  114. Laughlin-Tommaso SK, Khan Z, Weaver AL, Schleck CD, Rocca WA, Stewart EA. Cardiovascular risk factors and diseases in women undergoing hysterectomy with ovarian conservation. Menopause 2016;23(2):121–8. 10.1097/gme.000000000000050626173076
  115. Rocca WA, Grossardt BR, Shuster LT, Stewart EA. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neurodegener Dis 2012;10(1–4):175–8. 10.1159/00033476422269187
  116. Cusimano MC, Chiu M, Ferguson SE, Moineddin R, Aktar S, Liu N, Baxter NN. Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: population based cohort study. BMJ 2021;375:e067528. 10.1136/bmj-2021-06752834880044
  117. Public Health England. Research and Analysis. Reproductive Health: What Women Say. Information About the Gaps in Data and Services in Reproductive Health and Healthcare for Women. URL: https://www.gov.uk/government/publications/reproductive-health-what-women-say (accessed 23 January 2023).
  118. Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105(1):165–73.e4. 10.1016/j.fertnstert.2015.09.03226477496
  119. Liu JH, Soper D, Lukes A, Gee P, Kimble T, Kroll R, et al. Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2018;132(5):1241–51. 10.1097/aog.000000000000294230303900
  120. Simon JA, Catherino W, Segars JH, Blakesley RE, Chan A, Sniukiene V, Al-Hendy A. Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2018;131(3):431–9. 10.1097/aog.000000000000246229420395
  121. Cox J, Malik M, Britten J, Lewis T, Catherino WH. Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial. Reprod Sci 2018;25(2):198–206. 10.1177/193371911772880228929861
  122. Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: mechanisms and pathogenesis. Semin Reprod Med 2020;38(2-03):129–43. 10.1055/s-0040-171668733032339
  123. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res 2019;8. 10.12688/f1000research.17242.1
  124. Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for adenomyosis. Semin Reprod Med 2020;38(2-03):151–6. 10.1055/s-0040-171901633124017
  125. Capmas P, Brun JL, Legendre G, Koskas M, Merviel P, Fernandez H. Ulipristal acetate use in adenomyosis: a randomized controlled trial. J Gynecol Obstet Hum Reprod 2021;50(1):101978. 10.1016/j.jogoh.2020.10197833186772
  126. Osuga Y, Nakano Y, Yamauchi Y, Takanashi M. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial. Fertil Steril 2021;116(1):189–97. 10.1016/j.fertnstert.2021.01.02333715871
  127. Murji A, Crosier R, Chow T, Ye XY, Shirreff L. Role of ethnicity in treating uterine fibroids with ulipristal acetate. Fertil Steril 2016;106(5):1165–9. 10.1016/j.fertnstert.2016.06.01227336213
  128. Luyckx M, Squifflet JL, Jadoul P, Votino R, Dolmans MM, Donnez J. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014;102(5):1404–9. 10.1016/j.fertnstert.2014.07.125325241376
  129. Morgante G, Centini G, Troìa L, Orvieto R, De Leo V. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids. Reprod Biol Endocrinol 2020;18(1):50. 10.1186/s12958-020-00611-132430027
  130. Meaidi A, Kuhr Skals R, Alexander Gerds T, Lidegaard O, Torp-Pedersen C. Decline in Danish use of oral tranexamic acid with increasing use of the levonorgestrel-releasing intrauterine system: a nationwide drug utilization study. Contraception 2020;101(5):321–6. 10.1016/j.contraception.2019.12.01331935386
  131. Gatti M, Poluzzi E, De Ponti F, Raschi E. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. Drug Saf 2020;43(12):1277–85. 10.1007/s40264-020-00975-832748236
  132. Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med 2017;377(1):28–40. 10.1056/NEJMoa170008928525302
  133. Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LN, Gao W, Yang H, et al. Estimating the effect of elagolix treatment for endometriosis on postmenopausal bone outcomes: a model bridging phase III trials to an older real-world population. JBMR Plus 2020;4(12):e10401. 10.1002/jbm4.1040133354641
  134. Al-Hendy A, Lukes AS, Poindexter AN, 3rd, Venturella R, Villarroel C, Critchley HOD, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med 2021;384(7):630–42. 10.1056/NEJMoa200828333596357
  135. Herman MC, Penninx J, Geomini PM, Mol BW, Bongers MY. Choice of primary outcomes evaluating treatment for heavy menstrual bleeding. BJOG 2016;123(10):1593–8. 10.1111/1471-0528.1405427240106
  136. Cooper NAM, Rivas C, Munro MG, Critchley HOD, Clark TJ, Matteson KA, et al. Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set [published online ahead of print April 13 2023]. BJOG 2023. 10.1111/1471-0528.17473
  137. Khan K. The CROWN initiative: journal editors invite researchers to develop core outcomes in women’s health. BJOG 2016;123(Suppl 3):103–4. 10.1111/1471-0528.1436327627608
← DiscussionAcknowledgements →

Attribution. Lucy HR Whitaker; Lee J Middleton; Lee Priest; Smita Odedra; Versha Cheed; Elaine P Nicholls et al. (2023). Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: the UCON randomised controlled trial and mechanism of action study. National Institute for Health and Care Research. Copyright © 2023 Whitaker et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK596827. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support